Efficacy and Safety of Imatinib in Chordoma
This study has been completed.
First Posted: September 8, 2005
Last Update Posted: February 23, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||April 2008|
|Primary Completion Date:||April 2008 (Final data collection date for primary outcome measure)|
Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, Rowe JM, Schwarz M, Goldschmidt N, Nagler A. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010 Oct 1;116(19):4564-72. doi: 10.1002/cncr.25351. Erratum in: Cancer. 2011 Jan 1;117(1):230.